BioNTech Entered into an Exclusive Research Collaboration with Matinas BioPharma to Evaluate Novel Delivery Technology for mRNA-Based Vaccines
Shots:
- Matinas to receive an upfront & is also eligible to receive additional research funding from BioNTech. The companies will closely collaborate on formulation, optimization, and in vitro testing & also initiated the discussions on a license agreement for Matinas’ LNC platform technology
- The collaboration will combine BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) delivery platform technology to accelerate the novel formulations for mRNA vaccines including a potential formulation for oral vaccines
- Matinas’ LNC platforms have the potential to show an encouraging capability for intracellular & oral delivery
Ref: Globe Newswire | Image: BioNTech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
